Real-life experience with ixekizumab in plaque psoriasis : a multi-center, retrospective, 3-year study
BACKGROUND: Confirmatory data on the long-term effectiveness and safety of ixekizumab in psoriatic patients from real-world studies are needed.
OBJECTIVES: The primary aim was to evaluate the 3-year drug survival of ixekizumab in the treatment of patients with moderate-to-severe plaque psoriasis, in a multicenter real-world setting. The secondary aim was to assess the influence of predictive factors on the drug survival of ixekizumab.
METHODS: A retrospective analysis was performed on a cohort of patients with chronic plaque psoriasis, who received at least one dose of ixekizumab before December 2018. The drug survival analysis was performed and descriptively analyzed using Kaplan-Meier survival curves. Multivariable Cox regression analyses were carried out including variables considered to be of clinical importance.
RESULTS: A total of 306 patients were enrolled. The overall drug survival at 12, 24, and 36 months of treatment with ixekizumab was 92.11%, 83.85%, and 80.19%, respectively. A higher probability (HR 2.34) of drug withdrawal was found among patients who had already received an anti-IL-17 agent compared with bio-naive patients (p 0.017).
CONCLUSIONS: We found that ixekizumab is a biological agent characterized by long-term effectiveness, not influenced by several clinical factors and associated with a good safety profile.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Expert opinion on biological therapy - 23(2023), 4 vom: 17. Apr., Seite 365-370 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Caldarola, Giacomo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 01.05.2023 Date Revised 01.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14712598.2023.2193288 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354327526 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354327526 | ||
| 003 | DE-627 | ||
| 005 | 20231226061959.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14712598.2023.2193288 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1181.xml |
| 035 | |a (DE-627)NLM354327526 | ||
| 035 | |a (NLM)36927246 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Caldarola, Giacomo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-life experience with ixekizumab in plaque psoriasis |b a multi-center, retrospective, 3-year study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.05.2023 | ||
| 500 | |a Date Revised 01.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Confirmatory data on the long-term effectiveness and safety of ixekizumab in psoriatic patients from real-world studies are needed | ||
| 520 | |a OBJECTIVES: The primary aim was to evaluate the 3-year drug survival of ixekizumab in the treatment of patients with moderate-to-severe plaque psoriasis, in a multicenter real-world setting. The secondary aim was to assess the influence of predictive factors on the drug survival of ixekizumab | ||
| 520 | |a METHODS: A retrospective analysis was performed on a cohort of patients with chronic plaque psoriasis, who received at least one dose of ixekizumab before December 2018. The drug survival analysis was performed and descriptively analyzed using Kaplan-Meier survival curves. Multivariable Cox regression analyses were carried out including variables considered to be of clinical importance | ||
| 520 | |a RESULTS: A total of 306 patients were enrolled. The overall drug survival at 12, 24, and 36 months of treatment with ixekizumab was 92.11%, 83.85%, and 80.19%, respectively. A higher probability (HR 2.34) of drug withdrawal was found among patients who had already received an anti-IL-17 agent compared with bio-naive patients (p 0.017) | ||
| 520 | |a CONCLUSIONS: We found that ixekizumab is a biological agent characterized by long-term effectiveness, not influenced by several clinical factors and associated with a good safety profile | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Efficacy | |
| 650 | 4 | |a ixekizumab | |
| 650 | 4 | |a psoriasis | |
| 650 | 4 | |a real-life | |
| 650 | 4 | |a safety | |
| 650 | 7 | |a ixekizumab |2 NLM | |
| 650 | 7 | |a BTY153760O |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Chiricozzi, A |e verfasserin |4 aut | |
| 700 | 1 | |a Megna, M |e verfasserin |4 aut | |
| 700 | 1 | |a Dapavo, P |e verfasserin |4 aut | |
| 700 | 1 | |a Giunta, A |e verfasserin |4 aut | |
| 700 | 1 | |a Burlando, M |e verfasserin |4 aut | |
| 700 | 1 | |a Malagoli, P |e verfasserin |4 aut | |
| 700 | 1 | |a Dini, V |e verfasserin |4 aut | |
| 700 | 1 | |a Mariani, M |e verfasserin |4 aut | |
| 700 | 1 | |a Fabbrocini, G |e verfasserin |4 aut | |
| 700 | 1 | |a Quaglino, P |e verfasserin |4 aut | |
| 700 | 1 | |a Bianchi, L |e verfasserin |4 aut | |
| 700 | 1 | |a Parodi, A |e verfasserin |4 aut | |
| 700 | 1 | |a Peris, K |e verfasserin |4 aut | |
| 700 | 1 | |a De Simone, C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on biological therapy |d 2001 |g 23(2023), 4 vom: 17. Apr., Seite 365-370 |w (DE-627)NLM116190124 |x 1744-7682 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:4 |g day:17 |g month:04 |g pages:365-370 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14712598.2023.2193288 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 4 |b 17 |c 04 |h 365-370 | ||